REGN logo Regeneron Pharmaceuticals +
Regeneron Pharmaceuticals
+

Regeneron Pharmaceuticals Competitors & Alternatives

Regeneron Pharmaceuticals competitors and alternatives include Moderna, etc.…

Jump
Company
Company
Ticker
REGN
MRNA
Headquarter
Tarrytown ,NY
US
Cambridge ,MA
US
CEO
Leonard S. Schleifer
Stephane Bancel
Industry
Biotechnology
Biotechnology
Stock Price
Stock Price
Market Cap
Market Cap
$59.45 B
$9.25 B
Employees
Years
  • 2022
  • 2023
  • 2024
  • 2022
  • 2023
  • 2024
Employees
  • 11.85 K
  • 13.45 K
  • 15.11 K
  • 3.90 K
  • 5.60 K
  • 5.80 K
Y/Y
14.3%
13.49%
12.31%
44.44%
43.59%
3.57%

Income Statement

Revenue
Years
  • 2022
  • 2023
  • 2024
  • 2022
  • 2023
  • 2024
Revenue
  • $12.17 B
  • $13.12 B
  • $14.20 B
  • $18.88 B
  • $6.85 B
  • $3.20 B
Y/Y
24.26%
7.76%
8.27%
6.42%
63.72%
53.29%
Revenue by Products / Services
Revenue by Geography
Research and Development
Years
  • 2022
  • 2023
  • 2024
  • 2022
  • 2023
  • 2024
Research and Development
  • $3.06 B
  • $3.99 B
  • $4.62 B
  • $3.30 B
  • $4.85 B
  • $4.54 B
Y/Y
16.56%
30.45%
15.99%
65.49%
47.04%
6.23%
Operating Income
Years
  • 2022
  • 2023
  • 2024
  • 2022
  • 2023
  • 2024
Operating Income
  • $5.39 B
  • $4.35 B
  • $4.17 B
  • $9.42 B
  • -$4.24 B
  • -$3.95 B
Y/Y
39.8%
19.26%
4.02%
29.15%
145%
6.94%
Tax Rate (%)
Years
  • 2022
  • 2023
  • 2024
  • 2022
  • 2023
  • 2024
Tax Rate (%)
  • 11.00%
  • 6.00%
  • 8.00%
  • 13.00%
  • -20.00%
  • 1.00%
Y/Y
20.13%
45.38%
31.28%
55.46%
254.54%
106.54%
Net Income
Years
  • 2022
  • 2023
  • 2024
  • 2022
  • 2023
  • 2024
Net Income
  • $4.34 B
  • $3.95 B
  • $4.41 B
  • $8.36 B
  • -$4.71 B
  • -$3.56 B
Y/Y
46.28%
8.87%
11.61%
31.47%
156.37%
24.46%
Revenue Per Employee
Years
  • 2022
  • 2023
  • 2024
  • 2022
  • 2023
  • 2024
Revenue Per Employee
  • $1.03 M
  • $975.26 K
  • $940.16 K
  • $4.84 M
  • $1.22 M
  • $551.55 K
Y/Y
33.74%
5.05%
3.6%
26.32%
74.73%
54.9%
Net Income Per Employee
Years
  • 2022
  • 2023
  • 2024
  • 2022
  • 2023
  • 2024
Net Income Per Employee
  • $366.08 K
  • $293.95 K
  • $292.11 K
  • $2.14 M
  • -$841.79 K
  • -$613.97 K
Y/Y
53%
19.7%
0.63%
52.56%
139.26%
27.06%

Assets & Liabilities | Cash Flow

Total Assets
Years
  • 2022
  • 2023
  • 2024
  • 2022
  • 2023
  • 2024
Total Assets
  • $29.21 B
  • $33.08 B
  • $37.76 B
  • $25.86 B
  • $18.43 B
  • $14.14 B
Y/Y
14.86%
13.23%
14.15%
4.82%
28.74%
23.25%
Total Liabilities
Years
  • 2022
  • 2023
  • 2024
  • 2022
  • 2023
  • 2024
Total Liabilities
  • $6.55 B
  • $7.11 B
  • $8.41 B
  • $6.74 B
  • $4.57 B
  • $3.24 B
Y/Y
1.73%
8.5%
18.27%
36%
32.12%
29.11%
Capital Expenditures (Capex)
Years
  • 2022
  • 2023
  • 2024
  • 2022
  • 2023
  • 2024
Capital Expenditures (Capex)
  • -$590.10 M
  • -$926.40 M
  • -$755.90 M
  • -$400.00 M
  • -$707.00 M
  • -$1.05 B
Y/Y
6.92%
56.99%
18.4%
40.85%
76.75%
48.66%

Profitability

Operating Income Margin (%)
Years
  • 2022
  • 2023
  • 2024
  • 2022
  • 2023
  • 2024
Operating Income Margin (%)
  • 44.24%
  • 33.15%
  • 29.39%
  • 49.91%
  • -61.90%
  • -123.32%
Y/Y
20.53%
25.07%
11.34%
33.43%
224.02%
99.22%
Net Income Margin (%)
Years
  • 2022
  • 2023
  • 2024
  • 2022
  • 2023
  • 2024
Net Income Margin (%)
  • 35.64%
  • 30.14%
  • 31.07%
  • 44.30%
  • -68.84%
  • -111.32%
Y/Y
29.07%
15.43%
3.09%
35.61%
255.4%
61.71%
EBITDA
Years
  • 2022
  • 2023
  • 2024
  • 2022
  • 2023
  • 2024
EBITDA
  • $5.26 B
  • $4.69 B
  • $5.32 B
  • $9.77 B
  • -$3.28 B
  • -$3.39 B
Y/Y
45.61%
10.77%
13.31%
27.79%
133.61%
3.38%
Free Cash Flow (FCF)
Years
  • 2022
  • 2023
  • 2024
  • 2022
  • 2023
  • 2024
Free Cash Flow (FCF)
  • $4.42 B
  • $3.67 B
  • $3.66 B
  • $4.58 B
  • -$3.83 B
  • -$4.06 B
Y/Y
32.23%
17.11%
0.08%
65.65%
183.5%
6.01%

Ratios

Return on Equity (ROE)
Years
  • 2022
  • 2023
  • 2024
  • 2022
  • 2023
  • 2024
Return on Equity (ROE)
  • 19.14%
  • 15.22%
  • 15.03%
  • 43.73%
  • -34.03%
  • -32.67%
Y/Y
55.52%
20.48%
1.25%
49.3%
177.82%
4%
Return on Assets (ROA)
Years
  • 2022
  • 2023
  • 2024
  • 2022
  • 2023
  • 2024
Return on Assets (ROA)
  • 14.85%
  • 11.95%
  • 11.69%
  • 32.34%
  • -25.58%
  • -25.18%
Y/Y
53.23%
19.53%
2.18%
34.61%
179.1%
1.56%
Debt to Equity
Years
  • 2022
  • 2023
  • 2024
  • 2022
  • 2023
  • 2024
Debt to Equity
  • 11.92%
  • 10.41%
  • 9.21%
  • 6.28%
  • 8.97%
  • 6.85%
Y/Y
17.11%
12.67%
11.53%
3.09%
42.83%
23.63%

Valuation

Enterprise Value
Years
  • 2022
  • 2023
  • 2024
  • 2022
  • 2023
  • 2024
Enterprise value
  • $76.87 B
  • $93.69 B
  • $77.08 B
  • $68.77 B
  • $36.33 B
  • $14.79 B
Y/Y
15.48%
21.88%
17.73%
28.68%
47.17%
59.29%
Enterprise value to Revenue
Years
  • 2022
  • 2023
  • 2024
  • 2022
  • 2023
  • 2024
Enterprise value to Revenue
  • 6.31
  • 7.14
  • 5.43
  • 3.64
  • 5.30
  • 4.62
Y/Y
52.46%
13.11%
24.01%
32.99%
45.6%
12.86%
Enterprise value to EBITDA
Years
  • 2022
  • 2023
  • 2024
  • 2022
  • 2023
  • 2024
Enterprise value to EBITDA
  • 14.61
  • 19.96
  • 14.49
  • 7.04
  • -11.06
  • -4.36
Y/Y
112.29%
36.59%
27.39%
1.23%
257.17%
60.63%

Related company

Submit feedback to Bullfincher